A C Shaw1, K Kalidas, A H Crosby, S Jeffery, M A Patton. 1. Medical Genetics Unit, LG Floor, Jenner Wing, St George's, University of London, Cranmer Terrace, London, UK. adam.shaw@nhs.net
Abstract
OBJECTIVE: To define better the adult phenotype and natural history of Noonan syndrome. DESIGN: A prospective observational study of a large cohort. RESULTS: Data are presented for 112 individuals with Noonan syndrome (mean age 25.3 (range 12-71) years), who were followed up for a mean of 12.02 years. Mutations in PTPN11 were identified in 35% of probands. Ten subjects died during the study interval; three of these deaths were secondary to heart failure associated with hypertrophic cardiomyopathy. Pulmonary stenosis affected 73 (65%) subjects; 42 (58%) required no intervention, nine underwent balloon pulmonary valvuloplasty (three requiring further intervention) and 22 surgical valvuloplasty (three requiring further intervention). Hypertrophic cardiomyopathy affected 21 (19%) patients, which had remitted in two cases, but one subject required cardiac transplant. No subjects died suddenly or had symptoms suggestive of arrhythmia. The mean final adult height was 167.4 cm in males and 152.7 cm in females. Feeding problems in infancy were identified as a predictor of future outcome. The mean age of speaking in two-word phrases was 26 months for those with no feeding difficulties, compared with 39 months for those with severe problems requiring nasogastric feeding. Attendance at a school for children with special needs for the same groups was 12.5% and 58%, respectively. A statement of special educational need had been issued in 44% overall; however, academic achievement was broadly similar to that of the general population. IMPLICATIONS: Although the morbidity for some patients with Noonan syndrome is low, early predictors of poorer outcome have been identified, which will help ascertain those most in need of intervention.
OBJECTIVE: To define better the adult phenotype and natural history of Noonan syndrome. DESIGN: A prospective observational study of a large cohort. RESULTS: Data are presented for 112 individuals with Noonan syndrome (mean age 25.3 (range 12-71) years), who were followed up for a mean of 12.02 years. Mutations in PTPN11 were identified in 35% of probands. Ten subjects died during the study interval; three of these deaths were secondary to heart failure associated with hypertrophic cardiomyopathy. Pulmonary stenosis affected 73 (65%) subjects; 42 (58%) required no intervention, nine underwent balloon pulmonary valvuloplasty (three requiring further intervention) and 22 surgical valvuloplasty (three requiring further intervention). Hypertrophic cardiomyopathy affected 21 (19%) patients, which had remitted in two cases, but one subject required cardiac transplant. No subjects died suddenly or had symptoms suggestive of arrhythmia. The mean final adult height was 167.4 cm in males and 152.7 cm in females. Feeding problems in infancy were identified as a predictor of future outcome. The mean age of speaking in two-word phrases was 26 months for those with no feeding difficulties, compared with 39 months for those with severe problems requiring nasogastric feeding. Attendance at a school for children with special needs for the same groups was 12.5% and 58%, respectively. A statement of special educational need had been issued in 44% overall; however, academic achievement was broadly similar to that of the general population. IMPLICATIONS: Although the morbidity for some patients with Noonan syndrome is low, early predictors of poorer outcome have been identified, which will help ascertain those most in need of intervention.
Authors: A Sarkozy; E Conti; D Seripa; M C Digilio; N Grifone; C Tandoi; V M Fazio; V Di Ciommo; B Marino; A Pizzuti; B Dallapiccola Journal: J Med Genet Date: 2003-09 Impact factor: 6.318
Authors: Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb Journal: Nat Genet Date: 2003-06 Impact factor: 38.330
Authors: Peter Hammond; Tim J Hutton; Judith E Allanson; Linda E Campbell; Raoul C M Hennekam; Sean Holden; Michael A Patton; Adam Shaw; I Karen Temple; Matthew Trotter; Kieran C Murphy; Robin M Winter Journal: Am J Med Genet A Date: 2004-05-01 Impact factor: 2.802
Authors: Luciana Musante; Hans G Kehl; Frank Majewski; Peter Meinecke; Susann Schweiger; Gabriele Gillessen-Kaesbach; Dagmar Wieczorek; Georg K Hinkel; Sigrid Tinschert; Maria Hoeltzenbein; Hans-Hilger Ropers; Vera M Kalscheuer Journal: Eur J Hum Genet Date: 2003-02 Impact factor: 4.246
Authors: Mary Ella Pierpont; Martina Brueckner; Wendy K Chung; Vidu Garg; Ronald V Lacro; Amy L McGuire; Seema Mital; James R Priest; William T Pu; Amy Roberts; Stephanie M Ware; Bruce D Gelb; Mark W Russell Journal: Circulation Date: 2018-11-20 Impact factor: 29.690
Authors: E A Croonen; W Nillesen; C Schrander; M Jongmans; H Scheffer; C Noordam; J M T Draaisma; I van der Burgt; H G Yntema Journal: Mol Syndromol Date: 2013-05-08
Authors: Michael Kraft; Ion Cristian Cirstea; Anne Kathrin Voss; Tim Thomas; Ina Goehring; Bilal N Sheikh; Lavinia Gordon; Hamish Scott; Gordon K Smyth; Mohammad Reza Ahmadian; Udo Trautmann; Martin Zenker; Marco Tartaglia; Arif Ekici; André Reis; Helmuth-Guenther Dörr; Anita Rauch; Christian Thomas Thiel Journal: J Clin Invest Date: 2011-08-01 Impact factor: 14.808
Authors: Jae-Sung Yi; Yan Huang; Andrea T Kwaczala; Ivana Y Kuo; Barbara E Ehrlich; Stuart G Campbell; Frank J Giordano; Anton M Bennett Journal: JCI Insight Date: 2016-12-08
Authors: Angela E Lin; Craig T Basson; Elizabeth Goldmuntz; Pilar L Magoulas; Deborah A McDermott; Donna M McDonald-McGinn; Elspeth McPherson; Colleen A Morris; Jacqueline Noonan; Catherine Nowak; Mary Ella Pierpont; Reed E Pyeritz; Alan F Rope; Elaine Zackai; Barbara R Pober Journal: Genet Med Date: 2008-07 Impact factor: 8.822